RT Journal Article
SR Electronic
T1 Changes in COVID-19-related mortality across key demographic and clinical subgroups: an observational cohort study using the OpenSAFELY platform on 18 million adults in England
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.30.22278161
DO 10.1101/2022.07.30.22278161
A1 ,
A1 Nab, Linda
A1 Parker, Edward PK
A1 Andrews, Colm D
A1 Hulme, William J
A1 Fisher, Louis
A1 Morley, Jessica
A1 Mehrkar, Amir
A1 MacKenna, Brian
A1 Inglesby, Peter
A1 Morton, Caroline E
A1 Bacon, Sebastian CJ
A1 Hickman, George
A1 Evans, David
A1 Ward, Tom
A1 Smith, Rebecca M
A1 Davey, Simon
A1 Dillingham, Iain
A1 Maude, Steven
A1 Butler-Cole, Ben FC
A1 O’Dwyer, Thomas
A1 Stables, Catherine L
A1 Bridges, Lucy
A1 Bates, Christopher
A1 Cockburn, Jonathan
A1 Parry, John
A1 Hester, Frank
A1 Harper, Sam
A1 Zheng, Bang
A1 Williamson, Elizabeth J
A1 Eggo, Rosalind M
A1 Evans, Stephen
A1 Goldacre, Ben
A1 Tomlinson, Laurie A
A1 Walker, Alex J
YR 2022
UL http://medrxiv.org/content/early/2022/08/02/2022.07.30.22278161.abstract
AB Objectives To quantify in absolute and relative terms how population-level COVID-19 death rates have changed in demographic and clinical subgroups.Design Retrospective cohort study on behalf of NHS England.Setting Linked primary care and death registry data from the OpenSAFELY-TPP platform, covering the first three pandemic waves in England (wave 1: March 23 to May 30, 2020; wave 2: September 7, 2020 to April 24, 2021; and wave 3, delta: May 28 to December 14, 2021).Participants In total, 18.7, 18.8, and 18.7 million adults were included for waves 1, 2, and 3 respectively.Main outcome measures COVID-19-related mortality based on linked death registry records.Results The crude absolute COVID-19-related death rate per 1,000 person-years decreased from 4.48 in wave 1 (95%CI 4.41;4.55), to 2.70 in wave 2 (95%CI 2.67;2.73), to 0.64 in wave 3 (95%CI 0.63;0.66). The absolute death rate decreased by 90% between waves 1 and 3 in patients aged 80+, but by only 20% in patients aged 18-39. This higher proportional reduction in age- and sex-standardised death rates was also seen for other groups, such as neurological disease, learning disability and severe mental illness. Conversely, standardised death rates in transplant recipients stayed constant across successive waves at 10 per 1,000 person-years. There was also only a small decrease in death rates between waves in people with kidney disease, haematological malignancies or conditions associated with immunosuppression. Consequently, the relative hazard of COVID-19-related death decreased over time for some variables (e.g. age), remained similar for some (e.g. sex, ethnicity), and increased for others (e.g. transplant).Conclusions COVID-19 death rates decreased over the first three pandemic waves. An especially large decrease was seen in older age groups and people with neurological disease, learning disability or severe mental illness. Some demographic inequalities in death rates persisted over time. Groups more likely to experience impaired vaccine effectiveness did not see the same benefit in COVID-19 mortality reduction.Competing Interest StatementAll authors declare the following: over the past five years BG has received research funding from the Laura and John Arnold Foundation, the NHS National Institute for Health Research (NIHR), the NIHR School of Primary Care Research, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK (HDRUK), the Health Foundation, and the World Health Organisation; he also receives personal income from speaking and writing for lay audiences on the misuse of science. RME is funded by HDR-UK and the MRC. EJW holds grants from MRC.Clinical Protocols https://github.com/opensafely/covid_mortality_over_time/blob/main/docs/Protocol_Covid19_related_death_over_time.pdf Funding StatementThis research used data assets made available as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058). In addition, the OpenSAFELY Platform is supported by grants from (222097/Z/20/Z); MRC (MR/V015757/1, MC_PC-20059, MR/W016729/1); NIHR (NIHR135559, COV-LT2-0073), and Health Data Research UK(HDRUK2021.000, 2021.0157). BGs work on better use of data in healthcare more broadly is currently funded in part by: the Bennett Foundation, the Wellcome Trust, NIHR Oxford Biomedical Research Centre, NIHR Applied Research Collaboration Oxford and Thames Valley, the Mohn-Westlake Foundation; all Bennett Institute staff are supported by BGs grants on this work. RME is funded by HDR-UK and the MRC. EJW holds grants from MRC. The views expressed are those of the authors and not necessarily those of the NIHR, NHS England, UK Health Security Agency (UKHSA) or the Department of Health and Social Care. Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (reference 21863).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to the underlying identifiable and potentially re-identifiable pseudonymised electronic health record data is tightly governed by various legislative and regulatory frameworks, and restricted by best practice.CIconfidence intervalSARS-CoV-2severe acute respiratory syndrome coronavirus 2COVID-19Coronavirus disease 2019BMIbody mass indexCKDchronic kidney diseaseRRTrenal replacement therapyIMDindex of multiple deprivationSTPSustainability and Transformation Partnership region